Resveratrol-loaded nanoparticles conjugated with kidney injury molecule-1 as a drug delivery system for potential use in chronic kidney disease

• Published in: Nanomedicine (London, England) Vol. 12; no. 22; pp. 2741 - 2756
• Main Authors: Lin, Yuh-Feng, Lee, Yu-Hsuan, Hsu, Yung-Ho, Chen, Yi-Jie, Lin, Yuan-Feng, Cheng, Fong-Yu, Chiu, Hui-Wen
• Format: Journal Article
• Language: English
• Published: England Future Medicine Ltd 01.11.2017
• Subjects: Alzheimer's disease; Animals; Antibodies - chemistry; Autophagy; Autophagy - drug effects; Bioavailability; Cell Line; Cell Survival; chronic kidney disease; Creatinine - metabolism; Cytokines; Diabetes; Drug Carriers - chemistry; Drug Liberation; Epithelial Cells - cytology; Hepatitis A Virus Cellular Receptor 1 - chemistry; Hepatitis A Virus Cellular Receptor 1 - immunology; Humans; inflammasome; Inflammasomes - metabolism; Inflammation; Interleukin-1beta - metabolism; Kidney diseases; kidney injury molecule-1; Kidney Tubules - cytology; Kinases; Lactic Acid - chemistry; Male; Mice; Mice, Inbred C57BL; Nanoparticles; Nanoparticles - chemistry; Nephritis, Interstitial - drug therapy; NLR Family, Pyrin Domain-Containing 3 Protein - metabolism; Oxidative stress; Polyglycolic Acid - chemistry; Proteins; Renal Insufficiency, Chronic - drug therapy; resveratrol; Stilbenes - administration & dosage; Stilbenes - chemistry; Stilbenes - pharmacokinetics; United States > US; chronic kidney disease; autophagy; kidney injury molecule-1; resveratrol; inflammasome

We used resveratrol (Res)-loaded nanoparticles (Res NPs) as a novel method for improving the pharmacokinetic properties of Res and analyzed the effect of Res NPs in chronic kidney disease (CKD). We coupled anti-kidney injury molecule-1 antibodies to Res NPs and analyzed safety and efficacy. Res NPs...